Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model.
<h4>Background</h4>The immunosuppressive mammalian target of rapamycin (mTOR) inhibitors are widely used in solid organ transplantation, but their effect on kidney disease progression is controversial. mTOR has emerged as one of the main pathways regulating cell growth, proliferation, di...
Main Authors: | Melania Kurdián, Inmaculada Herrero-Fresneda, Nuria Lloberas, Pepita Gimenez-Bonafe, Virginia Coria, María T Grande, José Boggia, Leonel Malacrida, Joan Torras, Miguel A Arévalo, Francisco González-Martínez, José M López-Novoa, Josep Grinyó, Oscar Noboa |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22427849/?tool=EBI |
Similar Items
-
EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01) -
The Role of Everolimus in Renal Cell Carcinoma
by: Malek Meskawi, et al.
Published: (2015-12-01) -
The use of everolimus in renal-transplant patients
by: Julio Pascual
Published: (2009-06-01) -
EVEROLIMUS IN THE TREATMENT FOR METASTATIC RENAL CANCER
by: B. Ya. Alekseyev, et al.
Published: (2014-07-01) -
EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
by: E. I. Prokopenko
Published: (2010-06-01)